NCT06462365 - Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 8, 2024

Primary Completion Date

April 15, 2026

Study Completion Date

April 15, 2027

Conditions

Hematologic MalignancyGvHDGVHD,AcuteGVHD, ChronicHematopoietic Stem Cell TransplantAcute Lymphoblastic Leukemia, Adult B-CellAcute Lymphoblastic Leukemia, Adult T-CellAcute Myeloid Leukemia in RemissionMyelodysplastic SyndromesChronic Myelomonocytic Leukemia, in RemissionCancer Remission

Interventions

BIOLOGICAL

TRX103

TRX103 infusion via central line.

Trial Locations (5)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

55455

RECRUITING

University of Minnesota, Minneapolis

91010

RECRUITING

City of Hope, Duarte

98109

RECRUITING

Fred Hutchinson Cancer Center, Seattle

02215

RECRUITING

Dana-Farber Cancer Institute, Boston

All Listed Sponsors

lead

Tr1X, Inc.

INDUSTRY